Graham Capital Management’s Royalty Pharma RPRX Stock Holding History

Graham Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$264K	Buy	+4,716	New	+$245K	﹤0.01%	947
2024 Q1	–	Sell	-8,847	Closed	-$249K	–	1276
2023 Q4	$249K	Sell	8,847 -19,965	-69%	-$549K	0.01%	781
2023 Q3	$782K	Sell	28,812 -82,994	-74%	-$2.46M	0.02%	430
2023 Q2	$3.44M	Buy	111,806 +96,014	+608%	+$3.25M	0.1%	137
2023 Q1	$569K	Sell	15,792 -55,279	-78%	-$2.05M	0.02%	708
2022 Q4	$2.81M	Buy	71,071 +54,917	+340%	+$2.29M	0.09%	165
2022 Q3	$649K	Buy	+16,154	New	+$690K	0.03%	656
2022 Q2	–	Sell	-44,459	Closed	-$1.73M	–	1211
2022 Q1	$1.73M	Buy	44,459 +39,142	+736%	+$1.54M	0.06%	160
2021 Q4	$211K	Buy	+5,317	New	+$207K	0.01%	449

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's RPRX Position: Q2 2026 in Review

Graham Capital Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 4,716 shares worth $264K. The stake represents ﹤0.01% of the portfolio and ranks #947 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in RPRX as recently as Q4 2023.

Graham Capital Management first reported a position in RPRX in Q4 2021 and has held it in 9 quarters since. The position peaked at $3.44M in Q2 2023. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Graham Capital Management held 4,716 shares of Royalty Pharma worth $264K as of Q2 2026.
Royalty Pharma was a new Graham Capital Management position in Q2 2026.
Royalty Pharma made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #947 holding.
Graham Capital Management first reported a position in Royalty Pharma in Q4 2021 and has held it in 9 quarters since.
Graham Capital Management's Royalty Pharma position peaked at $3.44M in Q2 2023.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.